Skip to content
Parse Biosciences logo — Scalable Single Cell Sequencing Without the Instrument

Parse Biosciences

Scalable Single Cell Sequencing Without the Instrument

Founded 2018 United States Seattle, United States 148 employees Acquired Total: $299.70M Biotechnology, Life Sciences +1

General Information

Company Name Parse Biosciences
Founded Year 2018
Location United States Seattle, United States
Founders / Decision Makers
Team member
Employees 148
Industries Biotechnology, Life Sciences, Clean Energy
Funding Stage Acquired
Business Model B2B, SaaS, Platform
Revenue Model Product Sales, Tiered Pricing, Service Fee
Hiring 4 roles posted in the month to 8 Nov 2026
Social

BounceWatch is an independent company data service, not affiliated with Parse Biosciences. To contact Parse Biosciences, visit parsebiosciences.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Parse Biosciences compare?

A PDF of Parse Biosciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Parse Biosciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Homepage Update

Significant changes detected on company website (30.9% content change).

Actively Hiring Nov 05, 2026

Hiring for 4 positions in the last 30 days.

New Partnership Nov 04, 2026

Oklahoma State University's NGS Core Facility is partnering to onboard Parse Biosciences single-cell RNA sequencing technology.

AI Insight

Bounce Watch AI
1 week ago

Post-acquisition, Parse Biosciences is demonstrating continued market penetration and strategic evolution. The new partnership with Oklahoma State University signals active adoption of its single-cell sequencing technology, while simultaneous hiring efforts and a significant website overhaul point to ongoing integration and a refreshed strategic direction under Qiagen's ownership.

Signal Types
Partnership Hiring Product
Strategic Labels
Market Expansion Integration Team Growth
Next Move: Expansion
·
Impact: 8/10
·
Ideal For: Life Sciences Investors — Post-Acquisition Growth

About Parse Biosciences

Parse Biosciences, founded in 2018 and headquartered in the United States, is a dynamic player in the Biotechnology and Life Sciences sectors. With a compelling slogan—"Scalable Single Cell Sequencing Without the Instrument"—the company is focused on revolutionizing single cell sequencing. Its innovative technology empowers researchers to advance in critical areas like cancer treatment, tissue repair, stem cell therapy, and understanding complex systems such as the immune system.

The company's value proposition lies in its ability to perform single cell sequencing with unprecedented scale and ease, a proposition that is attracting attention and investment. This global life sciences company recently received a substantial investment of $225.00M through an acquisition by Qiagen on 01 November 2025. These resources are likely to fuel further innovations and consolidate Parse Biosciences' pioneering role in facilitating groundbreaking discoveries within scientific research.

Business keywords: single cell sequencing, combinatorial cDNA barcoding, biotechnology startup, cancer research, tissue repair, stem cell therapy, kidney disease research, liver disease research, brain development research, immune system research, sample handling innovation, biological data analysis, non-microfluidic sequencing, fixed sample processing, scientific research acceleration

Services & Products

Single cell sequencing services
Whole transcriptome analysis
Data analytics for sequencing
Immune profiling (TCR and BCR)
Automation of sequencing workflows

Target Customers

Research laboratories Biotech companies Academic researchers Biomedical scientists Immunologists

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition $225.00M 1
Qiagen
01 Nov 2025
Debt Financing $25.00M 6
Marshall Wace, Bioeconomy Capital +4
01 Dec 2023
Series B $41.50M 5
Marshall Wace, Bioeconomy Capital +3
01 Feb 2022
Series A $7.00M 1
Bioeconomy Capital
01 Jan 2021
Seed $1.20M 1
Sahsen Ventures
01 Oct 2018
Spinout Undisclosed 1
University of Washington
01 Jan 2018

Parse Biosciences Alternatives & Competitors

View All Alternatives
Parse Biosciences vs
CS Genetics
CS Genetics United Kingdom

Disruptive platform for single-cell genomics which leverages instrument-free, solution-phase chemica...

24 employees
Biotechnology, Health Care
Parse Biosciences vs

The Pioneers in Molecular Cartography

Series B
71 employees
Biotechnology, Health Care
Parse Biosciences vs
Quantum-Si
Quantum-Si United States

The Protein Sequencing Company™

IPO
166 employees
Biotechnology, Health Care

FAQ About Parse Biosciences

Scalable Single Cell Sequencing Without the Instrument
Parse Biosciences was founded in 2018.
Parse Biosciences is headquartered in Seattle, United States.
Parse Biosciences operates in Biotechnology, Life Sciences and Clean Energy. Its work centres on single cell sequencing, combinatorial cDNA barcoding, biotechnology startup and cancer research. Its customers include Research laboratories, Biotech companies and Academic researchers.
Parse Biosciences has a B2B, SaaS and Platform business model. Its revenue comes from Product Sales, Tiered Pricing and Service Fee.
Parse Biosciences has approximately 148 employees.
Parse Biosciences has completed 6 funding rounds, raising a total of $299.70M. The latest funding stage is Acquired.
Parse Biosciences offers: Single cell sequencing services, Whole transcriptome analysis, Data analytics for sequencing, Immune profiling (TCR and BCR), Automation of sequencing workflows.
Top alternatives and competitors to Parse Biosciences include CS Genetics, Resolve Biosciences, Quantum-Si, Atrandi Biosciences, Ultima Genomics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Parse Biosciences and CS Genetics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Parse Biosciences, https://www.bouncewatch.com/company/parse-biosciences, updated 8 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout